Cargando…

First do no harm: uterine natural killer (NK) cells in assisted reproduction

Natural killer (NK) cells are a type of lymphocyte circulating in peripheral blood named because of their effector functions in killing target cells. Immune cells that share similar phenotypic characteristics but are poor killers populate the uterine lining at implantation and during early pregnancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Moffett, Ashley, Shreeve, Norman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472320/
https://www.ncbi.nlm.nih.gov/pubmed/25954039
http://dx.doi.org/10.1093/humrep/dev098
_version_ 1782377042603409408
author Moffett, Ashley
Shreeve, Norman
author_facet Moffett, Ashley
Shreeve, Norman
author_sort Moffett, Ashley
collection PubMed
description Natural killer (NK) cells are a type of lymphocyte circulating in peripheral blood named because of their effector functions in killing target cells. Immune cells that share similar phenotypic characteristics but are poor killers populate the uterine lining at implantation and during early pregnancy when the placenta is established. The functions of these uterine NK (uNK) cells are essentially unknown but available data point to a role in regulating placentation in concert with other elements of the decidua and invading trophoblast cells. Despite the lack of scientific rationale and advice from clinical governing bodies, such as the Human Fertilisation and Embryology Authority, an increasing range of tests and therapies are still offered to women undergoing IVF or attending recurrent miscarriage clinics based on the myth that uterine NK cells need suppressing to prevent damage to the embryo. New treatments can be introduced at whim with subsequent demands for expensive trials to prove/disprove their efficacy. The evidence that targeting uNK or peripheral blood NK cells assists women with recurrent pregnancy failure is lacking. Healthcare professionals and patients should very carefully evaluate the practice of immunomodulation to enhance pregnancy outcome. A discussion on how to move towards stricter regulation of immunotherapy in non-hospital settings is now needed because it is clear that the potential risks and costs of these therapies outweigh any benefits.
format Online
Article
Text
id pubmed-4472320
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44723202015-06-24 First do no harm: uterine natural killer (NK) cells in assisted reproduction Moffett, Ashley Shreeve, Norman Hum Reprod Debates Natural killer (NK) cells are a type of lymphocyte circulating in peripheral blood named because of their effector functions in killing target cells. Immune cells that share similar phenotypic characteristics but are poor killers populate the uterine lining at implantation and during early pregnancy when the placenta is established. The functions of these uterine NK (uNK) cells are essentially unknown but available data point to a role in regulating placentation in concert with other elements of the decidua and invading trophoblast cells. Despite the lack of scientific rationale and advice from clinical governing bodies, such as the Human Fertilisation and Embryology Authority, an increasing range of tests and therapies are still offered to women undergoing IVF or attending recurrent miscarriage clinics based on the myth that uterine NK cells need suppressing to prevent damage to the embryo. New treatments can be introduced at whim with subsequent demands for expensive trials to prove/disprove their efficacy. The evidence that targeting uNK or peripheral blood NK cells assists women with recurrent pregnancy failure is lacking. Healthcare professionals and patients should very carefully evaluate the practice of immunomodulation to enhance pregnancy outcome. A discussion on how to move towards stricter regulation of immunotherapy in non-hospital settings is now needed because it is clear that the potential risks and costs of these therapies outweigh any benefits. Oxford University Press 2015-07 2015-05-07 /pmc/articles/PMC4472320/ /pubmed/25954039 http://dx.doi.org/10.1093/humrep/dev098 Text en © The Author 2015. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Debates
Moffett, Ashley
Shreeve, Norman
First do no harm: uterine natural killer (NK) cells in assisted reproduction
title First do no harm: uterine natural killer (NK) cells in assisted reproduction
title_full First do no harm: uterine natural killer (NK) cells in assisted reproduction
title_fullStr First do no harm: uterine natural killer (NK) cells in assisted reproduction
title_full_unstemmed First do no harm: uterine natural killer (NK) cells in assisted reproduction
title_short First do no harm: uterine natural killer (NK) cells in assisted reproduction
title_sort first do no harm: uterine natural killer (nk) cells in assisted reproduction
topic Debates
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472320/
https://www.ncbi.nlm.nih.gov/pubmed/25954039
http://dx.doi.org/10.1093/humrep/dev098
work_keys_str_mv AT moffettashley firstdonoharmuterinenaturalkillernkcellsinassistedreproduction
AT shreevenorman firstdonoharmuterinenaturalkillernkcellsinassistedreproduction